BioInvent International AB Patents

Patent portfolio assigned to BioInvent International AB (verified via public assignee records). Estimated patent count: 170. Clinical-stage immuno-oncology antibody company (Lund, Sweden). Competitors from CB Insights profile; Exelixis is a licensing partner per BioInvent/Exelixis press. Patent count is approximate from Google Patents assignee search.